title: The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay.
authors.forename: Young-Hoon
authors.initials: YH
authors.lastname: Jeong
authors.forename: In-Suk
authors.initials: IS
authors.lastname: Kim
authors.forename: Bong-Ryong
authors.initials: BR
authors.lastname: Choi
authors.forename: Choong Hwan
authors.initials: CH
authors.lastname: Kwak
authors.forename: Jin-Yong
authors.initials: JY
authors.lastname: Hwang
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D023921:Coronary Stenosis / Q000628:therapy*; D003328:Coronary Thrombosis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D013988:Ticlopidine / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine